Astec Lifesciences Limited (IN:ASTEC)
:ASTEC
Top Page
Astec Lifesciences Limited
(ASTEC)
Select Model
Select Model
Rating:40Underperform
Price Target:
₹555.00
▼(-21.11% Downside)
Action:DowngradedDate:03/24/26
The score is driven primarily by weak financial performance (declining profitability, leverage risk, and negative cash generation). Technicals add downside bias due to a clear downtrend despite oversold readings, while valuation is constrained by losses and no provided dividend yield.
Positive Factors
Integrated manufacturing across actives, intermediates and formulations
Owning capability to produce technical actives, key intermediates and finished formulations creates vertical integration that supports margin capture, supply security and customer stickiness. Over months this reduces reliance on third-party suppliers and supports product-mix optimization.
Negative Factors
Declining revenue and negative margins
Sustained top-line contraction and falling gross profit undermine scale economics and long-run competitiveness. Negative net margins reduce internal reinvestment capacity and make margin recovery harder, pressuring long-term viability if revenue trends don't stabilize.
Read all positive and negative factors
Positive Factors
Negative Factors
Integrated manufacturing across actives, intermediates and formulations
Owning capability to produce technical actives, key intermediates and finished formulations creates vertical integration that supports margin capture, supply security and customer stickiness. Over months this reduces reliance on third-party suppliers and supports product-mix optimization.
Read all positive factors
Astec Lifesciences Limited (ASTEC) vs. iShares MSCI India ETF (INDA)
Market Cap
₹12.49B
Dividend YieldN/A
Average Volume (3M)412.49K
Price to Earnings (P/E)―
Beta (1Y)1.24
Revenue Growth1.54%
EPS Growth-8.04%
CountryIN
Employees606
SectorBasic Materials
Sector Strength58
IndustryAgricultural Inputs
Share Statistics
EPS (TTM)-7.00
Shares Outstanding22,282,238
10 Day Avg. Volume47,730
30 Day Avg. Volume412,490
Financial Highlights & Ratios
PEG Ratio-0.06
Price to Book (P/B)6.06
Price to Sales (P/S)3.73
P/FCF Ratio-47.04
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)12.7
Revenue Forecast (FY)₹6.66B
Astec Lifesciences Limited Business Overview & Revenue Model
Company Description
Astec LifeSciences Limited, together with its subsidiaries, manufactures, distributes, and sells agrochemicals active ingredients and pharmaceutical intermediates in India. It manufactures a range of fungicides, insecticides, herbicides, and inter...
How the Company Makes Money
Astec Lifesciences primarily makes money by selling agrochemical products across different points of the crop-protection value chain: (1) sale of active ingredients (technical) and key intermediates manufactured at its facilities to agrochemical c...
Astec Lifesciences Limited Financial Statement Overview
Summary
Income Statement
35
Negative
Balance Sheet
45
Neutral
Cash Flow
30
Negative
| Breakdown | TTM | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 3.78B | 3.81B | 4.58B | 6.28B | 6.77B | 5.55B |
| Gross Profit | 1.12B | -685.16M | 1.33B | 2.27B | 2.86B | 2.10B |
| EBITDA | -150.01M | -662.07M | -2.69M | 893.14M | 1.65B | 1.19B |
| Net Income | -1.14B | -1.35B | -469.30M | 255.65M | 898.59M | 650.49M |
Balance Sheet | ||||||
| Total Assets | 8.83B | 8.81B | 9.75B | 9.79B | 8.97B | 6.78B |
| Cash, Cash Equivalents and Short-Term Investments | 96.91M | 8.55M | 16.47M | 27.54M | 33.44M | 15.42M |
| Total Debt | 3.67B | 5.55B | 4.94B | 3.41B | 2.79B | 1.87B |
| Total Liabilities | 4.69B | 6.46B | 6.05B | 5.60B | 5.00B | 3.68B |
| Stockholders Equity | 4.14B | 2.35B | 3.69B | 4.19B | 3.96B | 3.09B |
Cash Flow | ||||||
| Free Cash Flow | -234.96M | -302.20M | -1.25B | -426.03M | -803.74M | -1.11B |
| Operating Cash Flow | -199.52M | -83.99M | 102.21M | 746.56M | 236.04M | -81.62M |
| Investing Cash Flow | -73.41M | -152.30M | -1.35B | -1.13B | -1.04B | -731.10M |
| Financing Cash Flow | 297.62M | 237.33M | 1.25B | 377.70M | 804.77M | 813.36M |
Astec Lifesciences Limited Technical Analysis
Neutral
703.50
Price Trends
601.72
Negative
659.21
Negative
739.72
Negative
Market Momentum
-18.65
Positive
45.69
Neutral
30.01
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:ASTEC, the sentiment is Neutral. The current price of 703.5 is above the 20-day moving average (MA) of 574.54, above the 50-day MA of 601.72, and below the 200-day MA of 739.72, indicating a bearish trend. The MACD of -18.65 indicates Positive momentum. The RSI at 45.69 is Neutral, neither overbought nor oversold. The STOCH value of 30.01 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for IN:ASTEC.
Astec Lifesciences Limited Peers Comparison
UnderperformOutperform
Sector (61)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
66 Neutral | ₹12.39B | -28.19 | ― | 2.59% | -10.71% | -40.89% | |
61 Neutral | $10.43B | 7.12 | -0.05% | 2.87% | 2.86% | -36.73% | |
60 Neutral | ₹23.73B | 29.38 | ― | 0.97% | 5.74% | 16.06% | |
56 Neutral | ₹12.12B | 26.88 | ― | 0.24% | 10.70% | 32.65% | |
49 Neutral | ₹7.53B | -10.64 | ― | 0.39% | ― | ― | |
46 Neutral | ₹6.71B | -247.22 | ― | 0.34% | ― | ― | |
40 Underperform | ₹12.49B | -25.02 | ― | ― | 1.54% | -8.04% |
* Basic Materials Sector Average
IN:ASTEC
Astec Lifesciences Limited
560.45
-139.89
-19.97%
IN:HERANBA
Heranba Industries Limited
188.30
-47.68
-20.21%
IN:IGPL
IG Petrochemicals Ltd.
402.35
-5.22
-1.28%
IN:IOLCP
IOL Chemicals & Pharmaceuticals Ltd.
80.83
19.93
32.72%
IN:PUNJABCHEM
Punjab Chemicals & Crop Protection Ltd.
988.10
-14.02
-1.40%
IN:UNIENTER
Uniphos Enterprises Limited
96.51
-53.75
-35.77%
Astec Lifesciences Limited Corporate Events
Astec Lifesciences fully exits small solar SPV stake in Clean Max Andes
Mar 9, 2026
Astec Lifesciences Limited has exited its investment in Clean Max Andes Private Limited, a special purpose vehicle created with Clean Max Enviro Energy Solutions for group captive solar power generation, by selling its entire 26% equity stake. The...
Astec LifeSciences Files SEBI Demat Compliance Certificate for December Quarter
Jan 13, 2026
Astec LifeSciences Limited has informed the Indian stock exchanges that it has received a compliance certificate from its registrar and share transfer agent, Bigshare Services Pvt. Ltd., for the quarter ended 31 December 2025, confirming adherence...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.